Article
Immunology
Rohan Willis, Thomas C. R. McDonnell, Charis Pericleous, Emilio B. Gonzalez, Alvaro Schleh, Zurina Romay-Penabad, Ian P. Giles, Anisur Rahman
Summary: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and pregnancy morbidity. The current treatment options have limitations, and there is a need for more targeted therapies. Researchers developed a modified protein variant using site-specific chemical addition of polyethylene glycol (PEG), which effectively inhibited thrombus formation caused by pathogenic antibodies. These findings provide further evidence supporting the potential efficacy of PEG-modified protein as a treatment option for APS.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Katarina Kmet'ova, Elena Lonina, Srilakshmi Yalavarthi, Jerrold S. Levine, Claire K. Hoy, Cyrus Sarosh, Kelsey Gockman, Alexandra E. Morris, Ajay Tambralli, Jacqueline A. Madison, Yu Zuo, Rebecca Subang, Joyce Rauch, Jason S. Knight
Summary: β2GPI can bind not only to phospholipids, but also to cell-free DNA and neutrophil extracellular traps (NETs). The study showed that β2GPI interacts with cell-free DNA and NETs in a dose-dependent manner, retarding their migration. The authors also demonstrated the presence of β2GPI-DNA complexes in the plasma of APS patients, suggesting a potential role of this interaction in autoimmunity.
CLINICAL IMMUNOLOGY
(2023)
Article
Medical Laboratory Technology
Sarra Melayah, Mariem Ghozzi, Ibtissem Ghedira, Amani Mankai
Summary: This study found that antiphospholipid antibodies (aPL) were common in patients with articular manifestations, mainly directed against beta(2)GPI. However, the role of these antibodies remains to be specified.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2023)
Review
Pharmacology & Pharmacy
Ariela Hoxha, Daniela Tormene, Elena Campello, Paolo Simioni
Summary: This study conducted a systematic review on the additional treatments used in refractory and high-risk antiphospholipid antibody syndrome (APS) pregnancies. The results showed that combination therapy with IVIG and PEX achieved a 100% live birth rate in refractory APS pregnancies, while Pravastatin, IA, and PEX showed higher live birth rates in high-risk APS pregnancies.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Rheumatology
Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, Mary-Carmen Amigo, Zahir Amoura, Danieli Andrade, Laura Andreoli, Bahar Artim-Esen, Tatsuya Atsumi, Tadej Avcin, Michael H. Belmont, Maria Laura Bertolaccini, D. Ware Branch, Graziela Carvalheiras, Alessandro Casini, Ricard Cervera, Hannah Cohen, Nathalie Costedoat-Chalumeau, Mark Crowther, Guilherme de Jesus, Aurelien Delluc, Sheetal Desai, Maria De Sancho, Katrien M. Devreese, Reyhan Diz-Kucukkaya, Ali Duarte-Garcia, Camille Frances, David Garcia, Jean-Christophe Gris, Natasha Jordan, Rebecca K. Leaf, Nina Kello, Jason S. Knight, Carl Laskin, Alfred I. Lee, Kimberly Legault, Steve R. Levine, Roger A. Levy, Maarten Limper, Michael D. Lockshin, Karoline Mayer-Pickel, Jack Musial, Pier Luigi Meroni, Giovanni Orsolini, Thomas L. Ortel, Vittorio Pengo, Michelle Petri, Guillermo Pons-Estel, Jose A. Gomez-Puerta, Quentin Raimboug, Robert Roubey, Giovanni Sanna, Surya V. Seshan, Savino Sciascia, Maria G. Tektonidou, Angela Tincani, Denis Wahl, Rohan Willis, Cecile Yelnik, Catherine Zuily, Francis Guillemin, Karen Costenbader, Doruk Erkan
Summary: This study developed new APS classification criteria with high specificity, including clinical and laboratory domains, and improved classification accuracy through weighting and stratification.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Immunology
Xue Peng, Xi Tan, Aiyun Xing
Summary: Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by recurrent thrombosis and pregnancy complications. Obstetrical APS (OAPS) specifically refers to APS in pregnant women. The classification criteria for OAPS have generated discussion due to the possibility of excluding certain patients. This article presents two cases of non-criteria OAPS with severe complications and discusses the diagnosis, treatment, and prognosis of this unusual antenatal event. It also provides an overview of the pathogenetic mechanisms and clinical features of OAPS.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Katja Perdan-Pirkmajer, Polona Zigon, Anja Boc, Eva Podovsovnik, Sasa Cucnik, Alenka Mavri, Ziga Rotar, Ales Ambrozic
Summary: This study suggests that negative aCL and/or anti-beta 2GPI at the time of acute DVT may not require further aPL testing, while LA should be checked after discontinuation of anticoagulant therapy. Positive aCL and/or anti-beta 2GPI at the time of acute DVT have a strong positive predictive value for APS and may impact therapeutic decisions.
Review
Immunology
Juan J. Fierro, Manuela Velasquez, Angela P. Cadavid, Karina de Leeuw
Summary: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis and pregnancy-related complications, associated with persistent positivity of antiphospholipid antibodies (aPL). Antibodies against ss2GP1 (ass2GP1) play a crucial role in the pathogenesis of APS and may be used for obstetric risk stratification. Targeted therapies aimed at ss2GP1 could potentially prevent pregnancy morbidity in APS.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
(2022)
Article
Immunology
Giuseppe Barilaro, Emmanuel Coloma-Bazan, Alejandro Chacur, Carlo Della Rocca, Albert Perez-Isidro, Estibaliz Ruiz-Ortiz, Odette Vinas, Dolors Tassies Penella, Joan Carles Reverter, Alicia Molina Andujar, Ricard Cervera, Gerard Espinosa
Summary: The purpose of this study was to analyze the persistence of antiphospholipid antibodies (aPL) over time in patients with antiphospholipid syndrome (APS) and its association with clinical recurrence. The results showed that more than half of the patients maintained persistent positive aPLs over a long-term follow-up, and these patients were more prone to experience recurrence of clinical manifestations.
AUTOIMMUNITY REVIEWS
(2022)
Review
Hematology
Debbie Jiang, Wendy Lim, Mark Crowther, David Garcia
Summary: The presence of anti-B2GPI is weakly associated with thrombosis and inconsistently associated with obstetric complications, with very low-quality evidence and study heterogeneity preventing a quantitative assessment.
Article
Immunology
Michael A. Cole, Gloria F. Gerber, Shruti Chaturvedi
Summary: Complement is a major driver of antiphospholipid syndrome (APS) and a promising therapeutic target. Reliable, rapid-turnaround biomarkers are needed in APS to predict adverse clinical outcomes and determine who will benefit most from complement inhibition. Current studies highlight the inconsistencies in testing, suggesting that cell-based testing or multiplex panels may be most clinically relevant.
CLINICAL IMMUNOLOGY
(2023)
Article
Hematology
Paolo Macor, Paolo Durigutto, Monica Argenziano, Kate Smith-Jackson, Sara Capolla, Valeria Di Leonardo, Kevin Marchbank, Valerio Stefano Tolva, Fabrizio Semeraro, Concetta T. Ammollo, Mario Colucci, Roberta Cavalli, Pierluigi Meroni, Francesco Tedesco
Summary: A new targeted thrombolytic agent consisting of nanobubbles coated with recombinant tissue plasminogen activator (rtPA) and a recombinant antibody specific for cell-bound 132-GPI was developed. The targeted nanobubbles exhibited greater lysing capabilities for platelet-rich blood clots and induced rapid and persistent recanalization of occluded vessels in animal models. This study suggests that targeting cell-bound 132-GPI may be an effective and thrombus-specific thrombolytic strategy.
Review
Biochemistry & Molecular Biology
Svetlana Vrzic Petronijevic, Aleksandra Vilotic, Zanka Bojic-Trbojevic, Sanja Kostic, Milos Petronijevic, Ljiljana Vicovac, Milica Jovanovic Krivokuca
Summary: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL). Women with APS are at high risk of recurrent early pregnancy loss and late obstetrical complications. In addition to vascular thrombosis, research has found that aPL has a direct negative effect on placental cells, which is a major mechanism of obstetric APS.
Review
Biochemistry & Molecular Biology
Alex A. Gandhi, Shanea K. Estes, Christine E. Rysenga, Jason S. Knight
Summary: Antiphospholipid syndrome (APS) is a leading cause of thrombosis, with pathogenic antibodies circulating at stable levels in blood, but thrombotic events often requiring a second hit. Investigators have turned to animal models to explore APS mechanisms, with each model having potential advantages and disadvantages.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Microbiology
Marc Emmenegger, Sreedhar Saseendran F. Kumar, Vishalini J. Emmenegger, Tomas J. Malinauskas, Thomas Buettner, Laura Rose, Peter Schierack, Martin B. Sprinzl, Clemens Sommer, Karl B. Lackner, Adriano Aguzzi, Dirk B. Roggenbuck, Katrin B. M. Frauenknecht
Summary: SARS-CoV-2 infection can lead to diverse symptoms, with some patients developing hypercoagulation and autoantibody responses. Research has shown that infection with SARS-CoV-2 can result in the production of autoantibodies, particularly IgM antibodies targeting coagulation proteins. Further investigation is needed to explore the relationship between SARS-CoV-2 infection, autoantibody production, and disease severity.
Article
Hematology
Vittorio Pengo, Gentian Denas
Summary: Unprovoked or provoked by mild risk factors, VTE in young patients, VTE in uncommon sites, or cases of unexplained VTE recurrence may be positive for antiphospholipid antibodies (aPL) and thus may be diagnosed with antiphospholipid syndrome (APS). The evaluation of aPL is standardized using immunological tests for anticardiolipin and anti-beta 2-glycoprotein I. The determination of functional antibodies (lupus anticoagulant) is less standardized, especially in patients on anticoagulant treatment. Patients positive for all three tests are at high risk of recurrence, which may lead to chronic thromboembolic pulmonary hypertension. Randomized clinical trials have shown that triple-positive patients should be treated with vitamin K antagonists maintaining an international normalized ratio between 2 and 3. Whether patients with VTE and incomplete aPL profile can be treated with direct oral anticoagulants should be further investigated.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2023)
Review
Medicine, General & Internal
Irene Cecchi, Massimo Radin, Silvia Grazietta Foddai, Marta Arbrile, Alice Barinotti, Elena Rubini, Alessandro Morotti, Vittorio Pengo, Dario Roccatello, Savino Sciascia
Summary: Antiphospholipid syndrome (APS) is an autoimmune condition characterized by thrombosis and/or pregnancy morbidity in patients with persistent positive antiphospholipid antibodies (aPL). Patients who do not completely fulfill the classification criteria for overt APS may pose challenges in terms of treatment and management. This article aims to discuss therapeutic strategies based on available literature for challenging scenarios of aPL positive patients.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Candrika D. Khairani, Antoine Bejjani, Gregory Piazza, David Jimenez, Manuel Monreal, Saurav Chatterjee, Vittorio Pengo, Scott C. Woller, Josefina Cortes-Hernandez, Jean M. Connors, Yogendra Kanthi, Harlan M. Krumholz, Saskia Middeldorp, Anna Falanga, Mary Cushman, Samuel Z. Goldhaber, David A. Garcia, Behnood Bikdeli
Summary: A systematic review and meta-analysis of randomized controlled trials comparing direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) for thrombotic antiphospholipid syndrome patients found that DOACs were associated with an increased risk of subsequent arterial thrombotic events compared to VKAs. However, there were no significant differences in the risk of subsequent venous thromboembolic events or major bleeding between the two groups.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Hematology
Elena Pontara, Maria Grazia Cattini, Elisa Bison, Chunyan Cheng, Gentian Denas, Vittorio Pengo
Summary: This study evaluated the role of phospholipids in reversing aPS/PT-mediated APC-R. The findings indicate that phospholipids can reverse the resistance, possibly due to changes in phospholipid availability.
THROMBOSIS RESEARCH
(2022)
Review
Medicine, General & Internal
Rui Zhu, Gang-Yi Cheng, Gentian Denas, Vittorio Pengo
Summary: Acquired thrombophilia, specifically antiphospholipid antibodies (aPL), may contribute to the development of chronic thromboembolic pulmonary hypertension (CTEPH). Young patients who experience an unprovoked pulmonary embolism (PE) or PE triggered by mild risk factors should be tested for aPL. If positive, close monitoring and lifelong anticoagulant therapy should be considered because aPL-induced thrombophilia increases the risk of recurrent PE leading to CTEPH. The presence of lupus anticoagulant (LAC), anti-cardiolipin (aCL), and anti-& beta;2-glycoprotein I (a & beta;2GPI) antibodies indicates the highest risk of recurrence and necessitates treatment with warfarin for maximum protection.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Rheumatology
Cecilia B. Chighizola, Francesca Pregnolato, Danieli Andrade, Maria Tektonidou, Vittorio Pengo, Guillermo Ruiz-Irastorza, H. Michael Belmont, Maria Gerosa, Paul Fortin, D. Ware Branch, Laura A. Andreoli, Michelle A. Petri, Ricard S. Cervera, Jason S. Knight, Rohan Willis, Maria Efthymiou, Hannah Cohen, Doruk Erkan, Maria Laura Bertolaccini
Summary: The study aims to evaluate the antibodies titers against beta(2)-glycoprotein I (anti-beta(2)GPI) and domain 1 (anti-D1) in a longitudinally manner. The results show that treatment with hydroxychloroquine (HCQ) is associated with a decrease in antibody titers, while incident vascular events are associated with an increase in antibody titers. The titers of antibodies are lower at the time of thrombosis. This study is of great importance in understanding the fluctuations in antibody titers and their relationship with thrombosis.
ARTHRITIS & RHEUMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Giovanni Santostasi, Gentian Denas, Vittorio Pengo
Summary: This article summarizes the progress made in using anticoagulation for stroke prevention in patients with non-valvular atrial fibrillation, with a particular focus on new drugs that can minimize bleeding risk in elderly patients.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Medicine, Research & Experimental
Elena Gkrouzman, Rohan Willis, Danieli Andrade, Maria G. Tektonidou, Vittorio Pengo, Guillermo Ruiz-Irastorza, H. Michael Belmont, Paul R. Fortin, Maria Gerosa, Flavio Signorelli, Tatsuya Atsumi, D. Ware Branch, Cecilia Nalli, Esther Rodriguez-Almaraz, Michelle A. Petri, Ricard Cervera, Jason S. Knight, Maria Efthymiou, Hannah Cohen, Maria Laura Bertolaccini, Doruk Erkan, Robert Roubey
Summary: A study found that different profiles of antiphospholipid antibody (aPL) are associated with the clinical manifestations of antiphospholipid syndrome (APS), particularly higher levels of anticardiolipin antibody (aCL) and anti -b2 glycoprotein-I antibody (ab2GPI). The study also identified overlapping antibody detection methods and proposed a calculation method to assess the overall burden of aPL.
LABORATORY INVESTIGATION
(2023)
Article
Rheumatology
Gustavo G. M. Balbi, Yasaman Ahmadzadeh, Maria G. Tektonidou, Vittorio Pengo, Savino Sciascia, Amaia Ugarte, H. Michael Belmont, Chary Lopez-Pedrera, Paul R. Fortin, Denis Wahl, Maria Gerosa, Guilherme R. de Jesus, Lanlan Ji, Tatsuya Atsumi, Maria Efthymiou, D. Ware Branch, Cecilia Nalli, Esther Rodriguez Almaraz, Michelle Petri, Ricard Cervera, Jason S. Knight, Bahar Artim-Esen, Rohan Willis, Maria Laura Bertolaccini, Hannah Cohen, Robert Roubey, Doruk Erkan, Danieli Castro Oliveira de Andrade
Summary: The objective of this study was to quantify the damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis, and to identify clinical and laboratory characteristics associated with damage in these patients. The study found that DIAPS is of great significance in identifying patients with a higher damage burden and selected traditional cardiovascular risk factors, steroid use, and specific aPL profiles may help in identifying these patients.
Letter
Hematology
Marta Monti, Tiziano Martini, Vittorio Pengo, Giovanni Poletti, Paola Pedrazzi, Chiara Biasoli, Maddalena Giovacchini, Tommaso Fasano
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2023)
Article
Rheumatology
Yu Zuo, Sherwin Navaz, Alex Tsodikov, Katarina Kmetova, Lyndsay Kluge, Amala Ambati, Claire K. Hoy, Srilakshmi Yalavarthi, Danieli de Andrade, Maria G. Tektonidou, Savino Sciascia, Vittorio Pengo, Guillermo Ruiz-Irastorza, H. Michael Belmont, Maria Gerosa, Paul R. Fortin, Guilherme Ramires de Jesus, D. Ware Branch, Laura Andreoli, Esther Rodriguez-Almaraz, Michelle Petri, Ricard Cervera, Rohan Willis, David R. Karp, Quan-Zhen Li, Hannah Cohen, Maria Laura Bertolaccini, Doruk Erkan, Jason S. Knight
Summary: This study aimed to investigate the presence, antigen specificities, and potential clinical associations of anti-neutrophil extracellular trap (anti-NET) antibodies in antiphospholipid (aPL) antibody-positive patients without lupus. The results showed that high levels of anti-NET antibodies were found in 45% of aPL-positive patients, and they were associated with clinical manifestations and the production of specific autoantibodies.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Immunology
Valerio Rasi, Kathleen R. Phelps, Keegan R. Paulson, Christopher S. Eickhoff, Mathivanan Chinnaraj, Nicola Pozzi, Marco Di Gioia, Ivan Zanoni, Shubha Shakya, Haley L. Carlson, David A. Ford, Grant R. Kolar, Daniel F. Hoft
Summary: This study reveals the crucial role of homodimeric GzmA structure in opsonization, phagocytosis, and elimination of Mycobacterium tuberculosis in human monocytes. It also highlights PDIA1 as a potential host-directed therapy for the prevention and treatment of tuberculosis.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Hematology
Suresh Kumar, John Wulf II, Katherine Basore, Nicola Pozzi
Summary: This study reveals that circulating β2-glycoprotein I is elongated and capable of binding to pathogenic anti-domain I antibodies. The binding is driven by the interaction with negatively charged phospholipids, which increases the local concentration of the antigen rather than dramatically changing its conformation.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Meeting Abstract
Rheumatology
Zeynep Belce Erton, Rebecca K. Leaf, Danieli Castro Oliveira de Andrade, Megan Barber, Maria G. Tektonidou, Vittorio Pengo, Savino Sciascia, Amaia Ugarte, H. Michael Belmont, Chary Lopez-Pedrera, Paul R. Fortin, Maria Gerosa, Guilherme de Jesus, Tatsuya Atsumi, Zhuoli Zhang, Hannah Cohen, D. Ware Branch, Denis Wahl, Laura Andreoli, Esther Rodriguez Almaraz, Michelle Petri, Ricard Cervera, Yu Ray Zuo, Bahar Artim-Esen, Rohan Willis, Maria Laura Bertolaccini, Robert Roubey, Doruk Erkan
ARTHRITIS & RHEUMATOLOGY
(2022)
Meeting Abstract
Rheumatology
Silvia Grazietta Foddai, Irene Cecchi, Massimo Radin, Danieli De Andrade, Maria Tektonidou, Vittorio Pengo, Guillermo Ruiz-Irastorza, H. Michael Belmont, Maria Gerosa, Paul Fortin, Rosario Lopez-Pedrera, Zhouli Zhang, Tatsuya Atsumi, Guilherme de Jesus, Hannah Cohen, Nina Kello, Ware Branch, Denis Wahl, Laura Andreoli, Esther Rodriguez, Michelle Petri, Ann E. Clarke, Ricard Cervera, Jason Knight, Bahar Artim-Esen, Rohan Willis, Guillermo Pons-Estel, Doruk Erkan, Dario Roccatello, Savino Sciascia
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Hematology
E. O. Artemenko, S. I. Obydennyi, K. S. Troyanova, G. A. Novichkova, D. Y. Nechipurenko, M. A. Panteleev
Summary: In this study, we investigated the adhesive properties of circulating plasma-derived and platelet-derived microvesicles (MVs) and their potential role in thrombus growth. The results showed that both types of MVs weakly bound fibrinogen but did not stably adhere to immobilized fibrinogen. Moreover, the presence of these MVs did not significantly affect thrombus formation. Therefore, MVs present in the plasma of healthy individuals are unlikely to directly contribute to thrombus formation under arterial flow conditions.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J. Favaloro
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marium Malik, Maha Al-Ghafry, Abraham Haimed, Julia Su, Maribel Lema, Linda Shore-Lessersson, Suchitra S. Acharya
Summary: This study analyzed and evaluated leukemia-associated coagulopathy in newly diagnosed pediatric leukemia patients using CCTs and ROTEM. The results showed that fibrinogen and platelets played a significant role in causing coagulopathies in this population. This suggests the utility of using CCTs and ROTEM in the pediatric population to evaluate hemostatic function and guide blood product replacement.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Mohammad M. Elahi, Alexandra N. Witt, Edward L. G. Pryzdial, Paul B. McBeth
Summary: Thrombotic disease may be underdiagnosed in microgravity conditions, and the underlying factors are still poorly understood. A case of internal jugular vein thrombosis was recently diagnosed in a low-risk female astronaut, and six out of ten additional crew members showed risk factors for jugular venous flow. Observations in space and studies on Earth suggest that microgravity affects blood flow, coagulation, and vascular function.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Stian Ingemann-Molden, Christina Krogner Caspersen, Nanna Rolving, Anette Arbjerg Hojen, Frederikus A. Klok, Erik L. Grove, Barbara Cristina Brocki, Jane Andreasen
Summary: This study found that no single PROM covered all aspects considered important by PE patients. PROMs recommended in the ICHOM core set covered most aspects, but worrisome thoughts, hypervigilance around symptoms, and uncertainty of illness were not covered.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Haomin Yan, Tsutomu Sasaki, Yasufumi Gon, Kumiko Nishiyama, Hideaki Kanki, Hideki Mochizuki
Summary: The incidence of cancer-associated stroke has increased with the prolonged survival times of cancer patients. In this study, the researchers focused on the driver gene KRAS and found that KRAS mutations exacerbated neurological deficits after stroke and promoted tumor growth. They also identified the upregulation of pro-inflammatory responses and the promotion of STAT3 phosphorylation in mice with KRAS mutations. Additionally, the researchers found that colorectal cancer patients with stroke onset within 3 months after cancer diagnosis had a worse prognosis.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Tomoki Togashi, Satomi Nagaya, Makiko Meguro-Horike, Haruto Matsumoto, Yuta Imai, Koichi Yamaguchi, Yoshinari Fujii, Haruka Moriya, Yuika Kikuchi, Ibuki Yasuda, Shin-ichi Horike, Eriko Morishita
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marta Najarro, Winnifer Briceno, Carmen Rodriguez, Alfonso Muriel, Sara Gonzalez, Ana Castillo, Ignacio Jara, Parth Rali, Catalin Toma, Behnood Bikdeli, David Jimenez
Summary: The CPES score is a useful tool in identifying the risk of hemodynamic deterioration in normotensive patients with acute PE, with acceptable C-statistic, excellent specificity, and low positive predictive value.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Lei Liu, Huifang Xu, Jian Wang, Haiyan Wang, Saisai Ren, Qian Huang, Mingyan Zhang, Hui Zhou, Chunyan Yang, Lu Jia, Yu Huang, Hao Zhang, Yanling Tao, Ying Li, Yanan Min
Summary: This study investigated the gut microbiota metabolites and cytokines, chemokines, and growth factors in patients with ITP and found their association with treatment responsiveness. The findings suggest that imbalanced secretion of cyto(chemo)kins/growth factors and inadequate levels of TMAO are characteristic of patients with ITP.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Roxanne Mcknight, Mohammad Salameh, Lee Ann Jones, Greta Anton, Lindsay Carter
Summary: This study evaluated the safety of fixed-dose heparin titration boluses in underweight patients with VTE. The results showed that although underweight patients required more frequent holding of heparin, there was no significant increase in bleeding risk.
THROMBOSIS RESEARCH
(2024)